SCHEMBL978071

SCHEMBL978071

CC(C)c1ccc(NC(=O)O)c(N)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.61
MAPT P10636 1/20 0.61
RAB9A P51151 1/20 0.61
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
ALOX12 P18054 1/20 0.50
HTT P42858 1/20 0.50
HIF1A Q16665 1/20 0.50
HDAC1 Q13547 10/20 0.43
HDAC3 O15379 9/20 0.42
NCOR2 Q9Y618 9/20 0.42
HDAC2 Q92769 8/20 0.42
FADS1 O60427 1/20 0.42
KIF11 P52732 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TRPA1 O75762 1/20 0.39
PTGS1 P23219 1/20 0.39
CACNA1C Q13936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29177278 0.79 MAPT (0.43) NPC1MAPTRAB9AHDAC1MEN1
SCHEMBL28816871 0.79 MAPK1 (0.45) NPC1MAPTRAB9AALDH1A1HDAC1
SCHEMBL978540 0.79 NPC1 (0.56) NPC1MAPTRAB9AALDH1A1GAA
SCHEMBL15009906 0.78 SMN1; SMN2 (0.50) NPC1MAPTRAB9AALDH1A1GAA
SCHEMBL1266865 0.77 HDAC1 (0.68) NPC1RAB9AALDH1A1HTTHDAC1
SCHEMBL21377412 0.76 ALDH1A1 (0.53) NPC1MAPTRAB9AALDH1A1GAA
SCHEMBL976683 0.74 KMT2A (0.56) NPC1MAPTRAB9AALDH1A1HTT
SCHEMBL976680 0.74 KMT2A (0.56) NPC1MAPTRAB9AALDH1A1HTT
SCHEMBL5936133 0.73 SMN1; SMN2 (0.41) NPC1MAPTRAB9AALDH1A1HTT
SCHEMBL3953891 0.73 HDAC1 (0.55) NPC1RAB9AALDH1A1GAAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440830-B2 Tetrahydro-fused pyridines as histone deacetylase inhibitors 4SC AG (DE) 2013-05-14 US disclosed
EP-2197552-B1 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2012-11-21 EP disclosed
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2011-01-27 US disclosed
EP-2197552-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2010-06-23 EP disclosed
WO-2009037001-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC3 NPC1 2881/4885MAPT 2144/4885RAB9A 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.